Rekah Pharmaceutical Industry Ltd

Rekah's capital structure is characterized by a debt-to-equity ratio of 1.11, indicating a moderate reliance on debt financing. The company holds cash and equivalents of 11,039,000 ILS, but its long-term debt of 173,395,000 ILS results in a net cash position that is negative after subtracting total debt. Free cash flow for the period was 6,234,000 ILS, suggesting some capacity to fund operations and investments without external financing.

Profitability metrics show a return on equity of 0.77% and a return on assets of 0.25%, both of which are below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. These figures suggest that the company is not generating strong returns relative to its equity and asset base.

Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. However, the absence of segment-specific revenue breakdowns implies that the company may not be diversifying its risk across multiple product lines or geographic regions, which is a common practice in the pharmaceutical industry to mitigate exposure to regulatory or market-specific risks.

The company's growth trajectory is not clearly defined in the available data. No specific revenue growth rates or future projections are provided, and the outlook for the current and next fiscal years is not quantified. This lack of forward-looking guidance makes it difficult to assess the company's potential for expansion or market penetration.

Risk factors include a medium liquidity risk, as the company's current ratio of 1.61 suggests it has sufficient short-term assets to cover its liabilities, but the negative net cash position after subtracting long-term debt indicates potential challenges in meeting long-term obligations. The risk of dilution is assessed as low, with no significant changes in shares outstanding between basic and diluted figures. However, the company's financial flexibility is constrained by its high debt load.

Recent events and filings do not provide specific details on new product launches, regulatory approvals, or strategic partnerships. The absence of recent transcripts or filings suggests a lack of public disclosure on material developments, which could affect investor confidence and market perception.

Rekah generated ILS 15.5 million in free cash flow in FY-4, demonstrating strong historical cash generation capabilities.

The company's cash conversion metric of 5.53 ranks as best-in-class compared to the pharmaceutical cohort median of 0.95.

Rekah returned to profitability in FY-4 with ILS 6.6 million net income, reversing previous years' net losses.

Operating income reached ILS 14.1 million in FY-4, indicating improved operational efficiency compared to the prior year.

Revenue maintained a positive four-year CAGR of 3.3%, suggesting underlying demand stability despite recent volatility.

The company carries a high credit risk flag, indicating significant concerns regarding its ability to meet financial obligations.

Debt-to-equity ratio stands at 1.11, placing Rekah in the bottom quartile of the pharmaceutical cohort for leverage.

Operating margin of 3.1% and net margin of 1.3% both fall below the pharmaceutical cohort medians.